智翔金泰：斯乐韦米单抗注射液获药物临床试验批准

Group 1 - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product, Sileweimi Monoclonal Antibody Injection [1] - The clinical trial is aimed at evaluating the passive immunity indication for children and adolescents aged 2 to 18 years who are suspected of rabies virus exposure [1]